Executives
-
Galvin RoyPresident, Global Plasma & BC -
Miller Laurie A.SVP, Human Resources
-
Simon, ChristopherPresident & CEO
-
Strong Stewart WPresident, Global Hospital
-
Lingamneni AnilaEVP, Chief Technology Officer
-
Llorens JosepEVP, Global Manufacturing
-
Basil Michelle LEVP and General Counsel
-
Maunsell Farris MaryanneVP, Chief Accounting Officer
-
Darecca JamesEVP, Chief Financial Officer
?
Dockendorff Charles J
Director
Haemonetics Corporation
US, Boston [HQ]
CIK
1400563
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
0
Price per Share :
$98.66
Equivalence :
$0.0
Transaction History
-
S0.0 Shares After TransactionValue : $n/aSold $2,868,742,000.00Transaction Date : 05/07/24
-
Footnotes
-
-
Footnotes:#1 The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on May 19, 2023.
-
A29,010,000 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/09/24
-
Footnotes
-
-
Footnotes:#1 Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.
-
A3,037 Shares After TransactionValue : $n/a$0.0Transaction Date : 03/07/24
-
Footnotes
-
-
Footnotes:#1 Represents restricted stock units which vest on the date of the 2025 Annual Meeting of Stockholders and are settled in shares of common stock.#2 Restricted stock units are settled in shares of common stock on a one-for-one basis.#3 Transaction pursuant to an existing Rule 10b5-1 trading plan adopted May 24, 2023.
-
S1,572 Shares After TransactionValue : $119,802.12Sold $111,647.65Transaction Date : 03/08/24
-
Footnotes
-
-
Footnotes:#1 Represents restricted stock units which vest on the date of the 2025 Annual Meeting of Stockholders and are settled in shares of common stock.#2 Restricted stock units are settled in shares of common stock on a one-for-one basis.#3 Transaction pursuant to an existing Rule 10b5-1 trading plan adopted May 24, 2023.
-
A4,433 Shares After TransactionValue : $n/a$0.0Transaction Date : 07/25/24
-
Footnotes
-
-
Footnotes:#1 The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.#2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.